C4 Therapeutics Stock Filter Stocks by Fundamentals
| CCCC Stock | USD 2.27 0.05 2.16% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess C4 Therapeutics' long-term financial health and intrinsic value.
CCCC | Shares Owned by Institutions | Build AI portfolio with CCCC Stock |
C4 Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of C4 Therapeutics from analyzing C4 Therapeutics' financial statements. These drivers represent accounts that assess C4 Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of C4 Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.5B | 288.3M | 280.5M | 322.5M | 306.4M | |
| Enterprise Value | 1.3B | 1.4B | 345.7M | 224.9M | 258.6M | 245.7M |
C4 Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, C4 Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to C4 Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
C4 Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in C4 Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of C4 Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing C4 Therapeutics' value.| Shares | State Street Corp | 2025-03-31 | 1.2 M | Bain Capital Life Sciences Investors, Llc | 2025-03-31 | 1.1 M | Tang Capital Management Llc | 2025-03-31 | 900 K | Silverarc Capital Management, Llc | 2025-03-31 | 882.3 K | Ubs Group Ag | 2025-03-31 | 872.8 K | Two Sigma Advisers, Llc | 2025-03-31 | 800.6 K | Jacobs Levy Equity Management, Inc. | 2025-03-31 | 697.7 K | Goldman Sachs Group Inc | 2025-03-31 | 622.7 K | Wells Fargo & Co | 2025-03-31 | 523.6 K | Soleus Capital Management, L.p. | 2025-03-31 | 7 M | Orbimed Advisors, Llc | 2025-03-31 | 6.8 M |
CCCC Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (2.60) % | ||||
| Operating Margin | (4.03) % | ||||
| Current Valuation | 14.02 M | ||||
| Shares Outstanding | 71.01 M | ||||
| Shares Owned By Insiders | 9.78 % | ||||
| Shares Owned By Institutions | 91.86 % | ||||
| Number Of Shares Shorted | 4.96 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 4.14 X | ||||
| Revenue | 35.58 M | ||||
| Gross Profit | (75.39 M) | ||||
| EBITDA | (103.37 M) | ||||
| Net Income | (105.32 M) | ||||
| Cash And Equivalents | 307.78 M | ||||
| Cash Per Share | 6.29 X | ||||
| Total Debt | 65.76 M | ||||
| Debt To Equity | 0.25 % | ||||
| Current Ratio | 6.90 X | ||||
| Book Value Per Share | 2.75 X | ||||
| Cash Flow From Operations | (65.16 M) | ||||
| Short Ratio | 6.29 X | ||||
| Earnings Per Share | (1.48) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 15.8 | ||||
| Number Of Employees | 110 | ||||
| Beta | 2.95 | ||||
| Market Capitalization | 164.74 M | ||||
| Total Asset | 349.6 M | ||||
| Retained Earnings | (633.7 M) | ||||
| Working Capital | 212.59 M | ||||
| Current Asset | 1 K | ||||
| Current Liabilities | 49 K | ||||
| Net Asset | 349.6 M |
About C4 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze C4 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether C4 Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of C4 Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of C4 Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on C4 Therapeutics Stock:Check out C4 Therapeutics Piotroski F Score and C4 Therapeutics Altman Z Score analysis. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Revenue Per Share | Quarterly Revenue Growth 1.382 | Return On Assets | Return On Equity |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.